148 related articles for article (PubMed ID: 16398469)
21. The epidemiology of glioma in adults: a "state of the science" review.
Ostrom QT; Bauchet L; Davis FG; Deltour I; Fisher JL; Langer CE; Pekmezci M; Schwartzbaum JA; Turner MC; Walsh KM; Wrensch MR; Barnholtz-Sloan JS
Neuro Oncol; 2014 Jul; 16(7):896-913. PubMed ID: 24842956
[TBL] [Abstract][Full Text] [Related]
22. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas.
Stockhammer F; Thomale UW; Plotkin M; Hartmann C; Von Deimling A
J Neurosurg; 2007 Apr; 106(4):633-7. PubMed ID: 17432715
[TBL] [Abstract][Full Text] [Related]
23. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
24. Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: results from the CCG-945 cohort.
Pollack IF; Finkelstein SD; Burnham J; Hamilton RL; Yates AJ; Holmes EJ; Boyett JM; Finlay JL
Pediatr Neurosurg; 2003 Sep; 39(3):114-21. PubMed ID: 12876389
[TBL] [Abstract][Full Text] [Related]
25. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
26. Molecular genetic markers as predictors of response to chemotherapy in gliomas.
Idbaih A; Omuro A; Ducray F; Hoang-Xuan K
Curr Opin Oncol; 2007 Nov; 19(6):606-11. PubMed ID: 17906460
[TBL] [Abstract][Full Text] [Related]
27. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
28. [Occurrence and molecular pathology of high grade gliomas].
Murnyák B; Csonka T; Hegyi K; Méhes G; Klekner A; Hortobágyi T
Ideggyogy Sz; 2013 Sep; 66(9-10):312-21. PubMed ID: 24358686
[TBL] [Abstract][Full Text] [Related]
29. An updated pooled analysis of glutathione S-transferase genotype polymorphisms and risk of adult gliomas.
Yao L; Ji G; Gu A; Zhao P; Liu N
Asian Pac J Cancer Prev; 2012; 13(1):157-63. PubMed ID: 22502660
[TBL] [Abstract][Full Text] [Related]
30. Microsatellite instability, PTEN and p53 germline mutations in glioma families.
Malmer B; Grönberg H; Andersson U; Jonsson BA; Henriksson R
Acta Oncol; 2001; 40(5):633-7. PubMed ID: 11669337
[TBL] [Abstract][Full Text] [Related]
31. Genetic epidemiology and risk factors for brain tumors.
Li X; Cao H; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):345-353. PubMed ID: 29774869
[TBL] [Abstract][Full Text] [Related]
32. Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.
Tabouret E; Nguyen AT; Dehais C; Carpentier C; Ducray F; Idbaih A; Mokhtari K; Jouvet A; Uro-Coste E; Colin C; Chinot O; Loiseau H; Moyal E; Maurage CA; Polivka M; Lechapt-Zalcman E; Desenclos C; Meyronet D; Delattre JY; Figarella-Branger D;
Acta Neuropathol; 2016 Oct; 132(4):625-34. PubMed ID: 27573687
[TBL] [Abstract][Full Text] [Related]
33. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors.
De Roos AJ; Rothman N; Inskip PD; Linet MS; Shapiro WR; Selker RG; Fine HA; Black PM; Pittman GS; Bell DA
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):14-22. PubMed ID: 12540498
[TBL] [Abstract][Full Text] [Related]
35. Survival and low-grade glioma: the emergence of genetic information.
Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M
Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286
[TBL] [Abstract][Full Text] [Related]
36. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
37. Pathological classification of brain tumors.
Pollo B
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology.
Walsh KM; Ohgaki H; Wrensch MR
Handb Clin Neurol; 2016; 134():3-18. PubMed ID: 26948345
[TBL] [Abstract][Full Text] [Related]
39. [How molecular biology can improve the clinical diagnosis of gliomas?].
D'Haene N; Blanchard O; De Nève N; Evens J; Maris C; Rorive S; Le Mercier M; Salmon I
Rev Med Brux; 2016; 37(3):152-158. PubMed ID: 28525188
[TBL] [Abstract][Full Text] [Related]
40. Cancer susceptibility variants and the risk of adult glioma in a US case-control study.
Egan KM; Thompson RC; Nabors LB; Olson JJ; Brat DJ; Larocca RV; Brem S; Moots PL; Madden MH; Browning JE; Ann Chen Y
J Neurooncol; 2011 Sep; 104(2):535-42. PubMed ID: 21203894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
